Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from ...

Needham upgraded Collegium Pharmaceutical (COLL) to Buy from Hold with a $46 price target The analyst cites the company’s topline and ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $28.50 and last traded at $28.56, with a ...

Short interest in Collegium Pharmaceutical Inc (NASDAQ:COLL) decreased during the last reporting period, falling from 6.29M to 6.11M. This put 23.48% of the company's publicly available shares short.

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...

GET MORE AI-GENERATED SIGNALS: January 03, 2025, 16:08 pm ET, BY Robert S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

View Collegium Pharmaceutical, Inc. (COLL) current and estimated P/E ratio data provided by Seeking Alpha.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...